A statement from Diabetes Australia about the withdrawal of Fiasp from the PBS 1 March 2023 Diabetes Australia has been advised that Fiasp insulin will be removed from the Pharmaceutical Benefits Scheme from 1 April 2023. This means people will no longer be able to access it at a subsidised price. Fiasp will be available for people who choose to access it via private prescription; however, this will be more expensive. We understand this is causing distress for some people living with diabetes who currently use this medication. We have conveyed our concerns to Novo Nordisk and the Government, and are continuing these discussions to see what can be done to reduce the impact on people living with diabetes who are using this medication. In the meantime, if you are using Fiasp, we strongly encourage you to make an appointment with your doctor as soon as possible to discuss alternative insulins. If you have any questions or concerns, please contact Diabetes Australia on 1800 177 055.
News 27 May 2026 Urgent product correction for MiniMed Android App Medtronic and the Therapeutic Goods Administration have issued an Urgent Product Correction for a MiniMed Mobile App Android software version... Continue Reading
News 27 May 2026 Tzield listing a game-changer for early-stage type 1 diabetes The first new therapy for type 1 diabetes in nearly a century, which works to delay the need for insulin therapy in type 1 diabetes, has been approved for use in Australia by the Therapeutic Goods Administration. Continue Reading
Blog 27 May 2026 How diabetes, depression, anxiety, and medicines are connected People with diabetes can be depressed or anxious more often than people without diabetes. Studies show that when you have diabetes, you are almost twice as likely to be depressed, regardless of the type of diabetes. Continue Reading
